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Objective: To determine the in vitro activity and inoculum effect of LY333328, a semisynthetic glycopeptide, against 
vancomycin-susceptible and vancomycin-resistant enterococcal isolates. 
Methods: One hundred and seventy-six enterococcal isolates (1 17 vancomycin-susceptible, 29 VanA-type and 30 VanC- 
type isolates) obtained from surveillance cultures of 139 intensive care unit patients were studied by the standard agar 
dilution method. Vancomycin resistance determinants were characterized by PCR. 
Results: The activity of LY333328 was comparable (MIC range, 0.1-2 mg/L) to those of vancomycin (0.1-4 mg/L) and 
teicoplanin (0.06-1 mg/L) for vancomycin-susceptible isolates. LY333328 was more active (0.143 mg/L) than vancomycin 
(256 to >lo24 mg/L) and teicoplanin (32-512 mg/L) against VanA-type isolates, and similar (0.2-1 mg/L) to teicoplanin 
(0.14.5 mg/L) against VanC-type isolates. The MIC distribution of LY333328 displayed a narrower range than that of 
vancomycin, with no clear distinction between susceptible and resistant populations. The increment in the inoculum 
size, from 104to 106CFU/spot, of susceptible isolates increased the MIC values of LY333328, vancomycin and teicoplanin 
by factors of 11.4,1.6 and 3.8, respectively. The corresponding factors for LY333328 for VanA-type and VanC-type isolates 
were 3.5 and 6.4, respectively. 
Conclusions: LY333328 displays an excellent in vitro activity against vancomycin-susceptible and -resistant enterococci. 
Nevertheless, the inoculum size used in susceptibility tests should be carefully controlled. 
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INTRODUCTION 
Although enterococcal infections are not usually 
considered to be associated with high mortality rates, 
the dramatic increase of multiresistant enterococcal 
strains has spurred interest in this pathogen [l]. During 
the last few years, glycopeptide-resistant enterococci 
(GRE) have emerged as a major public-health concern, 
particularly in intensive care units (ICUs) in institutions 
in the USA [2]. Progress has been made in defining risk 
factors for colonization or infection by these strains [3], 
and now several guidelines for the control and 
prevention of infections due to GRE have been 
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proposed [4], although precise treatment protocols 
remain to be defined. Penicillin G or aminopenicillins, 
alone or combined with an aminoglycoside, remain the 
therapy of choice for infections due to enterococci. 
The increased resistance to penicillins and high-level 
resistance to aminoglycosides observed in GRE have 
prompted a review of this regimen, as no effective 
antimicrobial therapy is available against many GRE 
[5]. Various combinations of cell wall-active antimicro- 
bials, includmg carbapenems and glycopeptides, have 
been successhlly assayed in a n m d  models [2,3]. Oral 
novobiocin and bacitracin have been used to suppress 
GRE fecal carriage, and a new streptogramin com- 
bination, quinupristin/dalfopristin, has been evaluated 
[5,6]. Lastly, recently developed glycopeptides have 
been shown to be active in vitro against GRE i7-10]. 
LY333328 is a semisynthetic glycopeptide derived 
&om the N-alkylation of LY264826, a naturally occur- 
ring glycopeptide with the same core structure as 
vancomycin [9]. Early reports have shown excellent 
antimicrobial activity of LY333328 against Gram- 
positive organisms, including staphylococci, strepto- 
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cocci and enterococci [8-111. The objective of this 
study was to compare the in vitro activity of LY333328 
against a collection of enterococcal isolates obtained 
from surveillance cultures derived from ICU patients. 
Organisms tested included both vancomycin-suscept- 
ible and -resistant enterococci. The inoculum effect in 
conventional media used for susceptibility testing was 
also investigated. 
MATERIALS AND METHODS 
The investigation was performed with enterococcal 
isolates recovered from survedance specimens of 139 
long-term intubated patients admitted to the ICU at 
a 400-bed teaching hospital during the period 1994- 
96. A hundred and sixty enterococcal isolates were 
obtained from rectal swabs and 16 isolates from nares, 
oropharynx and bronchial aspirates. Fifty-nine were 
vancomycin resistant and 117 vancomycin susceptible. 
Isolates were obtained by plating specimens on a 
commercial selective azide agar (m-Enterococcus agar, 
DIFCO, Detroit, Mi, USA) and additionally on 
selective azide agar supplemented with 6 mg/L of 
vancomycin. For identification of enterococci to the 
species level, the biochemical scheme of Facklam and 
Collins, and the criteria for motility and pigment 
production were used [12]. Pulsed-field gel electro- 
phoresis [13] was performed to avoid redundancy of 
repeated vancomycin-resistant isolates. When available, 
a single vancomycin-susceptible isolate per patient was 
also included for comparative purposes. 
LY333328 and vancomycin were obtained from 
Lilly Research Laboratories (Indianapolis, Ind., USA). 
The other antibiotics were obtained from the following 
manufacturers: Hoechst-Marion Roussel, Barcelona, 
Spain (teicoplanin); SmithKline Beecham, Madrid, 
Spain (ampicillin); and Merck Sharp & Dohme, 
Madrid, Spain (imipenem). MICs were determined by 
standard agar dilution method according to NCCLS 
criteria with an inoculum size of lo4 CFU/spot using 
Mueller-Hinton agar (Oxoid, Basingstoke, UK) [14]. 
For comparative purposes, MICs were also determined 
for 45 selected enterococcal isolates using standard 
broth microdilution [ 141. 
AU isolates with MIC values 2 4  mg/L of vanco- 
mycin were genetically typed by PCR to detect the 
presence of vanA, vanB, vanCl and vanC2 genes. DNA 
extraction was performed with the Instagene Matrix 
commercial kit (BioRad, Hercules, Ca, USA) accord- 
ing to the manufacturer’s instructions. Primers, reaction 
mixtures and PCR conditions followed published 
studies for the detection of vanA [15], vunB [16], 
vanCl [17] and vanC2 [18] genes. Enterococcus fuecium 
U2A1 [19], E.fecalis SF-299 (provided by George M. 
Eliopoulos), E .  gallinarum U2A3 [19] and E .  casselijlavus 
RYC46E (this study) were used as positive controls for 
the detection of vanA, van& vanCl and vanC2 genes, 
respectively. E.faecalis ATCC 29212 was used as nega- 
tive control. 
P-Lactamase production was assayed for all enter- 
ococcal isolates by incubating 50 pL of an overnight 
enterococcal culture with 50 pL of nitrocefin 100 mM 
at 35°C for 2 h. 
The inoculum size effect on MIC values (lo3, lo4, 
lo5 and lo6 CFU/spot) was studed in Mueller-Hinton 
agar with 45 selected isolates &splaying different levels 
of susceptibility to vancomycin and LY333328. In 
addition, the inoculum effect (lo3, lo4, lo5 and lo6 
CFU/mL) was also assayed by microdilution. Control 
strains were also included in the inoculum effect study. 
RESULTS AND DISCUSSION 
The glycopeptide-resistance genotype characteristics of 
the enterococcal isolates described in this study are 
listed in Table 1. Of the 176 isolates, 29 were positive 
for vanA PCR; 28 isolates contained the vanCl gene 
and two isolates contained the vanC2 gene. No VanB- 
type enterococcal isolates were isolated during the 
surveillance period. In Europe, in contrast to the USA, 
this situation is not unusual, as VanB isolates from 
surveillance cultures are much less common than VanA 
isolates [20-221. Moreover, in Spain the incidence of 
VanB isolates is particularly low [23]. It is of interest to 
note that, although E .  faecium represents the majority 
of GRE isolates recovered in the US [3,16], this species 
represents the minority of our VanA-type isolates 
(34.5%). On the other hand, in our study, 90.9% of the 
isolates were recovered from fecal samples. The 
epidemiologic relevance of these isolates derives from 
the suggestion that intestine is the reservoir of clinically 
relevant enterococcal isolates. Several studies have 
demonstrated that previous gastrointestinal coloniz- 
ation is a risk factor for infection with GRE [21,24]. 
LY333328 inhibits the same step in peptidoglycan 
biosynthesis as vancomycin [8,25]. It is highly active 
against Gram-positive organisms with MIC90 values 
10-100 times lower than that of vancomycin [7,10]. 
Previous studies have demonstrated that LY333328 
displays good inhibitory activity against both vancomycin- 
susceptible and -resistant Enterococcus isolates [7-11,261 
with a bactericidal concentration-dependent effect 
[ l l] .  Table 1 shows the activity of LY333328, vanco- 
mycin, teicoplanin and two p-lactam antibiotics against 
ICU isolates. Only one isolate of E .  faeciurn, susceptible 
to vancomycin, &splayed ampicillin MICs higher than 
16 mg/L. None of the enterococcal isolates produced 
0-lactamase. Table 2 shows the comparative activity of 
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Table 1 Activity of LY333328 against 176 enterocococcal isolates compared with those of two other glycopeptides and two 
D-lactam agents 
~~~~~ 
MIC ( mg/L) 
Organisms Van- 
(no. tested) genotype Antimicrobial Range 50% 90% Mode 
Et~terocoms - 
faecalis (103)' 
E .  faecium (1 1)' 
Enterococncc spp. 
(39" 
E,faecalis (19) 
E. faecium (10) 
vanA 
v a d  
E. gallinarum (28) vanC 
E. casselijlavus (2) vanC 
LY333328 
vancomycin 
teicoplanin 
ampicillin 
imipenem 
LY333328 
vancomycin 
teicoplanin 
ampicillin 
imipenem 
LY333328 
vancomycin 
teicoplanin 
ampicillin 
imipenem 
LY333328 
vancornycin 
teicoplanin 
ampicillin 
imipenem 
LY333328 
vancomycin 
teicoplanin 
ampicillin 
imipenem 
LY333328 
vancomycin 
teicoplanin 
ampican 
imipenem 
LY333328 
vancomycin 
teicoplanin 
ampicillin 
imipenem 
0.1-2 
0.1-4 
50.06-1 
0.1-8 
10.1-4 
0.1-1 
0.5-1 
0.1-1 
0.1-128 
0.2-256 
0.5-1 
2 
0.1-0.5 
0.2-1 
0.5-1 
2-8 
256 to >lo24 
32-512 
0.2-4 
0.5-2 
0.1-4 
512 to >lo24 
32-5 12 
1-16 
2-32 
0.2-1 
4-8 
0.1-0.5 
0 . 1 4  
0.2-8 
0.5-1 
4 
0.2 
0.2-0.5 
0.5-4 
0.5 
2 
0.2 
2 
1 
0.5 
1 
0.5 
1 
2 
- 
- 
- 
- 
- 
4 
>lo24 
256 
1 
1 
0.5 
1024 
64 
8 
8 
0.5 
8 
0.2 
0.5 
0.5 
- 
- 
- 
- 
- 
2 
2 
0.5 
4 
4 
1 
1 
0.5 
8 
16 
- 
- 
- 
- 
- 
8 
>I024 
512 
2 
2 
4 
21024 
128 
8 
16 
0.5 
8 
0.2 
2 
2 
- 
- 
- 
- 
- 
0.5 
2 
0.2 
2 
1 
0.5 
1 
0.5 
2 
2 
- 
- 
- 
- 
- 
4 
>lo24 
256 
1 
1 
0.2 
1024 
128 
8 
8/16 
0.2 
8 
0.2 
1 
0.5 
- 
- 
- 
- 
- 
"No v a d ,  vanB, vanC2 or vanC2 determinants amplified by PCR assays. 
b T ~ o  E.  durans and one E. avium. 
Table 2 Comparative in vitro activity of LY333328 against quality control and reference strains 
Glycopeptide MIC range (mg/L)' 
resistance 
Strain phenotype Vancomycin Teicoplanin LY333328 
Entemcorncrfaecalis ATCC 29212 2-4 0.2-0.5 0.2-0.5 
E .  faecium U2A1 VanA 1024 to 21024 128-512 1-4 
E .  fmcdis SF-299 VanB 16-32 0.060.2 0.2-1 
E. gallimrum U2A3 VanCl 4-8 0.2-0.5 0.2-1 
E. casselfivus RYC46E VanC2 4-8 0.2-0.5 0.2-0.5 
"Twelve determinations for each strain. 
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LY333328 against control strains used in PCR experi- 
ments and susceptibility testing. 
Considering all enterococcal isolates tested, 
LY333328 &splayed a high intrinsic activity, with 
MICSO/MIC~O of 0.5/2 mg/L. The corresponhng 
values for vancomycin and teicoplanin were 2/1024 
and 0.21128 mg/L, respectively. Against glycopeptide- 
susceptible enterococcal isolates, the modal MIC values 
for LY333328, vancomycin and teicoplanin were 0.5, 
2 and 0.2 mg/L, respectively. Vancomycin and 
LY333328 tend to present a better intrinsic activity 
against E. faecium than against E. faecalis, considering 
both vancomycin-resistant and -susceptible isolates. 
This trend is in agreement with the analysis of suscept- 
ibility data of vancomycin-susceptible strains reported 
in other publications by Jones et al [26] and could be 
confirmed from the data on vancomycin-susceptible 
enterococci in a recent European survey [27]. More- 
over, results from Fraise et al [7] show the higher 
activity of glycopeptides, including LY333328, against 
E. faecium vancomycin-resistant isolates. 
VanA-type E. faecalis and E. faecium isolates were 
inhibited by a concentration of LY333328 at least 256- 
and 64-fold lower than that required for inhibition 
with vancomycin or teicoplanin, respectively (Table 1). 
The modal MIC values of LY333328 for E. gallinartrm 
and E. casselijlavus were similar to those of teicoplanin 
(0.2 mg/L), but 40-fold lower than those of vanco- 
mycin (8 mg/L). The MIC5o/MIC90 of LY333328 
against VanC-type isolates was similar to that of 
teicoplanin. 
Figure 1 shows MIC distribution of all entero- 
coccal isolates tested, vancomycin susceptible and those 
with vanA and vanC determinants. Of note is the fact 
that vancomycin displayed a wide range of MIC 
distributions with clearly defined susceptible and 
VanA-type resistant populations, while LY333328 MIC 
values had a narrower range, without a clear gap 
between susceptible and VanA-type resistant popula- 
tions (Figure 1). This effect demonstrates the higher 
intrinsic activity of LY333328 compound against 
resistant isolates, which could be related to a secondary 
mechanism of inhibition [25]. Our results obtained 
with vancomycin-susceptible isolates and with E. 
gallinartrm and E. casselgavus (VanC type) are similar to 
those of previously reported investigations [9-111. In 
contrast, LY333328 MIC values observed for VanA- 
type isolates were slightly higher than those previously 
described [9,10]. A concentration of 4 mg/L of 
LY333328 inhibited 78.9% and 100% of highly 
vancomycin-resistant E. faecalis and E. faecium isolates, 
respectively. Twenty per cent (four of 19 isolates) 
of vancomycin-resistant E. faecalis isolates showed 
LY333328 MIC values of 8mg/L, which were 
Vancom ycin 
<O.l 0.2 0.5 1 2 4 B 18 32 64 128 258 512 ,512 
MIC (mg/L) 
Teicoplanin 
60 I 
! 60 
0 
.I 40 
0 
2 
- - 
0 20 
n 
40.1 0.2 0.5 1 2 4 8 16 32 64 128 256 512 >512 
MIC (mg/L) 
LY333328 -" I I 
+.I 0.2 0.5 1 2 4 8 16 32 64 128 256 512 ,512 
MIC lmg/L) 
Vancomycin susceptible VanC type I VanA type 
Figure 1 Distribution of vancomycin, teicoplanin and 
LY333328 MIC values for vancomycin-susceptible and 
-resistant (VanA-type and VanC-type) enterococcal 
isolates determined using an agar dilution method 
according to NCCLS guidelines [14]. 
repeatedly obtained in different agar dilution assays 
with an inoculum of lo4 CFU/spot. To our knowledge, 
the highest MIC value encountered for LY333328 in 
vancomycin-resistant enterococci was 4 mg/L [26]. As 
agar dilution may yield higher values for LY333328, we 
also investigated by a broth microdilution method 
(using an inoculum of lo5 CFU/mL) those E. faecalis 
isolates displaying 8 mg/L of LY333328. Using a 
microdilution methodology, LY333328 MIC values 
were 4 mg/L. Moreover, 45 selected isolates with 
hfferent levels of susceptibhty to glycopeptides yielded 
LY333328 MIC values by microdilution 1-2-fold 
dilution lower than those previously obtained by agar 
dilution. Nevertheless, the general form of MIC distri- 
bution obtained using microdilution-based methodo- 
logies did not differ from that of the agar dilution. 
Previous in vitro studies with a vancomycin- 
resistant E.  faecium and a methican-resistant Staphylo- 
coccus aureus strain have demonstrated that the bacteri- 
cidal activity of LY333328 is afEected by a large 
5 5 8  
10 - 
0 -  
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Agar dilution 
x MIC 
12 
10 - 
0 -  
6 -  
4 -  
2 -  
0 -  
- 
- 2  
- 4  
- 
1 o3 1 o4 1 o5 1 oB 
lnoculum size (CFU/spot) 
lnoculum size (CFU/mL) 
-LY333328 (Vancomycin-S) - 4 - LY333328 (VanA) 
- - - - LY333328 (VanC) 
+ Vancomycin (Vancomycin-S) 
Figure 2 Comparative activity of vancomycin, teicoplanin and LY333328 against 14 vancomycin-susceptible and 30 
vancomycin-resistant (21 VanA type, nine VanC type) enterococcal isolates with Werent inoculum sizes (expressed as fold- 
dilution change of MIC values). 
inoculum (107-10s CFU/mL), although a slight increase 
in drug concentration seems to compensate easily for 
this effect 1281. Our stuhes with 44 enterococcal isolates 
(14 vancomycin-susceptible, 21 VanA-type and nine 
VanC-type isolates) clearly demonstrate that LY333328 
MIC values were higher when the inoculum size was 
increased, both by agar and by microdilution methods. 
By agar dilution, an increment in the inoculum size, 
from lo4 to lo6 CFU/spot, in vancomycin-susceptible 
isolates increased MIC values of LY333328, vancomycin 
and teicoplanin by factors of 11.4, 1.6 and 3.8, 
respectively. The MIC values of LY333328 increased by 
factors of 3.4 for VanA-type and 6.4 for VanC-type 
isolates. By microdilution, the increment in the 
inoculum size, fkm lo4 to lo6 C F U / d ,  in susceptible, 
VanA-type and VanC-type isolates increased MIC 
values of LY333328 by factors of 5.4, 3.6 and 1.1, 
respectively (Figure 2). Moreover, for the reference 
VanB-type strain an incoculum effect was also observed 
for LY333328, with an increased factor of 5. This 
inoculum effect has not been previously reported. 
In summary, LY333328 shows high intrinsic 
activity against enterococci susceptible and resistant to 
currently available glycopeptides. This excellent in 
vitro activity and the bactericidal activity described by 
other authors [l 11 support the potential use of t h i s  new 
glycopeptide for the treatment of enterococcal 
infections, particularly in ICU patients, where resistant 
isolates are increasingly encountered. Our data suggest 
that the inoculum effect, an important factor in high- 
density infections, should be carefilly controlled in 
microbiological susceptibility stuhes with LY333328. 
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